Breast Cancer
Conditions
Keywords
margins, tumorectomy
Brief summary
We will observe if ICG fluorescence correlates with margins of breast tumours after iv injection of the contrast agent
Detailed description
In the operating room: ICG 0.25 mg/kg will be given as an iv injection at least 20 minutes before the beginning of the operation. The surgeon will remove the tumour (and the axillary lymph nodes) as usual. Optionally, peroperative in vivo imaging of the dissection of the tumour using the PDE camera will be performed. In the Laboratory of Pathology: The fresh tumorectomy piece will be processed as usual, and the thick sections for the evaluation of the margins as well as the tissues samples from each margins will be imaged using the PDE in comparison with the fluorescence in the mid part of the tumour and the fluorescent areas will be so delimited (and later analyzed in comparison with standards of known fluorescence intensity). After fixation, the tumoral tissues will be thereafter processed as usual. If fluorescent foci are identified at the level of the axillary piece (in case of CALND), they will be dissected and processed as other lymph nodes. Additionally, metastatic lymph nodes -if present- will also be controlled for their microscopic fluorescence or not. Using the near-infrared fluorescence microscope, the slides corresponding to the macroscopically fluorescent structures will be analyzed.
Interventions
DRUGIndocyanine Green
Observation of the correlation between fluorescence and margins of the tumour after IV injection of ICG
Sponsors
Jules Bordet Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with histopathological diagnosis of mammary cancer who are candidate for tumorectomy, either with SLN selective lymphadenectomy, or with complete axillary node dissection, * Informed consent form signed.
Exclusion criteria
* Diagnosis of mammary cancer established by gross biopsy, * Age less than18 years old. * Inability to give informed consent. * History of allergy or hypersensitivity against the investigational product (its active substance or ingredients), to iodine or to shellfish. * Apparent hyperthyroidism, autonomous thyroid adenoma, unifocal, multifocal or disseminated autonomies of the thyroid gland. * Documented coronary disease. * Advanced renal impairment (creatinine \> 1,5mg/dl). * During the 2 weeks before the enrolment, concurrent medication which reduces or increases the extinction of ICG (i.e. anticonvulsants, haloperidol and Heparin). * Pregnancy, breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Evaluation of the ability of NIR imaging to show (fluorescent) the tumoral volumes, the tumoral tissues to be analyzed by the pathologist, especially at the level of the operative margins | 17 months |
Secondary
| Measure | Time frame |
|---|---|
| - Analysis of the correlation between (levels of) ICG fluorescence and tumour margins as defined at the microscopic level by the pathologist | 17 months |
Countries
Belgium
Outcome results
None listed